Abstract:In order to increase the success rate in the development of oral drugs, an in vitro method, which can accurately estimate human oral absorption of a large variety of compounds from solid formulations, is required in the drug discovery stage. A dissolution/permeation (D/P) system is an in vitro system that simultaneously evaluates dissolution and permeation processes of drugs administered orally. In this study, we have investigated the advantages of a D/P system for use in the provisional estimation of human oral absorption of a drug (absorbed fraction, Fa) by applying it in its solid state. The D/P system mounted with a Madin-Darby canine kidney (MDCK) II cell monolayer was used to simultaneously evaluate the dissolved and the permeated amounts (% of dose) of 48 marketed drugs. Slightly modified, fasted-state simulated intestinal fluid (FaSSIFmod, 8 mL) was used as the apical medium of the D/P system. Each test drug was applied to the apical side of the D/P system as a suspension at one-hundredth of the clinical dose. The apparent permeability coefficient across the MDCK II cell monolayer was estimated in a buffer solution (pH 6.5). The octanol/water distribution coefficient (Log D) was measured at pH 6.5 by a flask shaking method. Transport medium (TM, pH 6.5), a buffer solution removing lecithin and taurocholate from FaSSIFmod, was used to determine the solubility at 24 h after applying drugs. The solubility in TM was used as a free drug concentration in FaSSIFmod. A good correlation was obtained between observed human Fa and the permeated amount in the D/P system. When the sigmoidal curve was obtained by the curve fitting to the data, the determination coefficient was R(2) = 0.79 and the 95% interval of the predicted Fa values was about ±24% for all drugs tested in the present study. For comparison, the permeated amount was calculated by multiplying the permeability of each drug (in vitro Papp) by the solubility in FaSSIFmod. However, the calculated permeated amount showed a lower correlation with the observed human Fa compared to the observed permeated amount in the D/P system. The ratio of the observed permeated amount to the calculated permeated amount was in inverse proportion to the ratio of solubility in FaSSIFmod to solubility in TM. This finding suggests the necessity of determining the free fraction of the dissolved drug in the gastrointestinal (GI) tract when calculating the human Fa. In the case of the D/P system, since applied drugs dissolved in FaSSIFmod first, and then only the free fraction permeated the membrane, an accurate estimation of the human Fa was possible from only the observed permeated amount. This in vitro system is expected to contribute to the selection of better compounds for oral use during the lead- and formulation-optimization processes in the drug discovery stage.

Evaluation of an Ussing Chamber System Equipped with Rat Intestinal Tissues to Predict Intestinal Absorption and Metabolism in Humans

Human small intestinal and colonic tissue mounted in the Ussing chamber as a tool for characterizing the intestinal absorption of drugs

Absorption Barriers in the Rat Intestinal Mucosa: 2. Application of Physiologically Based Mathematical Models to Quantify Mechanisms of Drug Permeation and Metabolism

In Vitro Digestion-In Situ Absorption Setup Employing a Physiologically Relevant Value of the Membrane Surface Area/Volume Ratio for Evaluating Performance of Lipid-Based Formulations: A Comparative Study with an In Vitro Digestion-Permeation Model

Validation of a Caco-2 microfluidic Chip model for predicting intestinal absorption of BCS Class I-IV drugs

Impact of gut permeability on estimation of oral bioavailability for chemicals in commerce and the environment

Simultaneous Evaluation of Membrane Permeability and UDP-Glucuronosyltransferase–Mediated Metabolism of Food-Derived Compounds Using Human Induced Pluripotent Stem Cell–Derived Small Intestinal Epithelial Cells

[Evaluation for impacts of gut wall metabolism of multiple components in Chuanxiong Rhizoma during intestinal absorption with S9 incubation]

The Ussing chamber system for measuring intestinal permeability in health and disease

Advantage of the Dissolution/Permeation System for Estimating Oral Absorption of Drug Candidates in the Drug Discovery Stage

Human intestinal fluid factors affecting intestinal drug permeation in vitro

Evaluation of intestinal absorption of ginsenoside Rg1 incorporated in microemulison using parallel artificial membrane permeability assay.

Significance of Basal Membrane Permeability of Epithelial Cells in Predicting Intestinal Drug Absorption

Usefulness of Human Jejunal Spheroid–Derived Differentiated Intestinal Epithelial Cells for the Prediction of Intestinal Drug Absorption in Humans

Gut Wall Metabolism. Application of Pre-Clinical Models for the Prediction of Human Drug Absorption and First-Pass Elimination

Validation of an Ex Vivo Permeation Method for the Intestinal Permeability of Different BCS Drugs and Its Correlation with Caco-2 In Vitro Experiments

ADME evaluation in drug discovery. 7. Prediction of oral absorption by correlation and classification.

In Situ Single-Pass Perfused Rat Intestinal Model for Absorption and Metabolism

Quantitative analysis of the impact of membrane permeability on intestinal first-pass metabolism of CYP3A substrates

Optimization of the Ussing chamber setup with excised rat intestinal segments for dissolution/permeation experiments of poorly soluble drugs

A hybrid evaluation of the intestinal absorption performance of compounds from molecular structure